[Epidermal growth factor (Heberprot-P®) in chronic ulcers]

Klappenbach R, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32017000285
Authors' recommendations: Evidence of low quality shows that intralesional injections of epidermal growth factor in chronic diabetic foot ulcers do not reduce the number of amputations although it may show a higher rate of ulcer healing. The evidence comes from placebo-controlled studies, not compared with other therapeutic treatments. There is no evidence assessing the use of epidermal growth factor in other chronic ulcers of different etiologies. Most clinical practice guidelines do not recommend using growth factor to treat chronic ulcers. This technology is commercially available mainly in Latin American and Asian countries and only some health systems in these countries cover it.
Project Status: Completed
Year Published: 2017
URL for published report: www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Epidermal Growth Factor
  • Humans
  • Skin Diseases
  • Stomach Ulcer
  • Ulcer
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.